Aurora Cannabis (ACB) Non-Current Deferred Tax Liability (2018 - 2025)
Aurora Cannabis (ACB) reported Non-Current Deferred Tax Liability of $2.5 million for Q4 2025, up 269.28% year-over-year from $675761.6 in Q4 2024, and down 1.37% quarter-over-quarter from $2.5 million in Q3 2025.
Aurora Cannabis (ACB) Non-Current Deferred Tax Liability (2018 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has 8 years of Non-Current Deferred Tax Liability data on file, last reported at $2.5 million in Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $2.5 million, up 269.28% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.5 million (up 269.28% YoY), and the FY2025 annual result was $1.3 million, down 89.0% from the prior year.
- Non-Current Deferred Tax Liability declined to $2.5 million in Q4 2025 per ACB's latest filing, from $2.5 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $109.0 million in Q2 2021 and troughed at $8876.4 in Q1 2023.
- A 5-year average of $13.4 million and a median of $11.4 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2021 and 2024: Non-Current Deferred Tax Liability sank 94.47% in 2021, then surged 135257.49% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $109.0 million in 2021, then tumbled by 88.93% to $12.1 million in 2022, then declined by 0.62% to $12.0 million in 2023, then tumbled by 94.37% to $675761.6 in 2024, then jumped by 269.28% to $2.5 million in 2025.
- Business Quant data shows ACB's Non-Current Deferred Tax Liability at $2.5 million in Q4 2025, $2.5 million in Q3 2025, and $1.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 675,761.59 |
| Dec 31, 2024 | 675,761.59 |
| Sep 30, 2024 | 11.37 Mn |
| Sep 30, 2024 | 11.37 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Jun 30, 2024 | 12.86 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | 11.99 Mn |
| Dec 31, 2023 | 11.99 Mn |
| Sep 30, 2023 | 12.36 Mn |
| Sep 30, 2023 | 12.36 Mn |